Huasun(SZ:000790) Zheng Quan Zhi Xing·2025-08-01 16:35Group 1 - The 16th meeting of the 13th Supervisory Board of Chengdu Huasheng Technology Group Co., Ltd. was held on August 1, 2025, via telecommunication, with all three supervisors present [1][2] - The Supervisory Board approved the performance commitment completion report for Tibet Kangyu Pharmaceutical Co., Ltd. for the year 2024, which showed a net profit of 16.7843 million yuan, falling short of the promised 20 million yuan, leading to a cash compensation requirement from Tibet Wan'an Pharmaceutical Information Consulting Co., Ltd. [1][2] - The Supervisory Board also approved the proposal to publicly transfer 51% of the equity of Tibet Kangyu, aligning with the company's future development plans and investment structure optimization [2]